Novartis Ag

Xenon Pharmaceuticals Inc.

Eli Lilly and Company

Natalia Pokrovskaia

Zaihui Zhang

Shaoyi Sun

Jianmin Fu

Vishnumurthy Kodumuru

Natalie Alysia Dales

Rajender Kamboj

Julia Fonarev

Duanjie Hou

Vandna Raina

Sultan Chowdhury

Serguei Sviridov

Shifeng Liu

John Gordon Allen

Qi Jia

Karin Briner

Maria Angeles Martinez-Grau

Richard C Hoying

Julie M Miyashiro

Andrew Caerwyn Williams

Christopher Stanley Galka

Roger Ryan Rothhaar

Richard Edmund Rathmell

Michael Philip Mazanetz

Matthew Robert Reinhard

Manuel Javier Cases-Thomas

Selma Sapmaz

Anne Marie Camp

The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.

Organic compounds

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I), where V, W, R, R, Rand Rare defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed. 

Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HTreceptor agonists for the treatment of 5-HTassociated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where Ris &#x2014;C&#x2261;C&#x2014;R, &#x2014;CH&#x2550;CRR, or &#x2014;(C-C)alkyl-Aroptionally substituted on the alkyl moiety with 1 to 6 fluoro substituents and other substituents are as defined in the specification. 

[object Object]

SCD1 inhibitors triazole and tetrazole compounds

Heterocyclic inhibitors of stearoyl-CoA desaturase

Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels

Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2C receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: R6 D R?N&#x2014;R&#x2033;R* where R6 is &#x2014;(CrC3)alkyl-S&#x2014;(C0-C3)alkyl-R10, &#x2014;(C1-C3)alkyl-NR11R12, &#x2014;(CrC3)alkyl-O&#x2014;R13. and other substituents are as defined in the specification. 

Growing community of inventors

New Westminster, Canada

Natalia Pokrovskaia